← Every company
Heron Therapeutics Inc Patents
What Heron Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
HRTX on carbonthat →Filings on file
9
Granted
3
Still pending
6
Filed under
2 names
9 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHOD OF ADMINISTERING EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTA61K 9/107, A61K 9/0019, A61K 31/438, A61K 31/496, A61K 31/5377, A61K 31/573, A61K 47/10, A61K 47/12, A61K 47/24, A61K 47/26, A61K 47/44Filed as Heron Therapeutics, Inc.2026-02-12Thomas B. Ottoboni | pending |
| METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTA61K 9/0019, A61K 9/107, A61K 31/5377, A61P 43/00, A61P 1/08, A61K 9/0024, A61K 31/573, A61K 47/10, A61K 47/12, A61K 47/18, A61K 47/24, A61K 47/26, A61K 47/44Filed as Heron Therapeutics, Inc.2025-04-04Thomas B. Ottoboni | pending |
| COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENTA61K 47/34, A61P 25/04, A61P 23/00, A61P 29/00, A61K 9/0019, A61K 9/0024, A61K 31/00, A61K 31/167, A61K 31/245, A61K 31/445, A61K 31/47, A61K 47/12Filed as Heron Therapeutics, Inc.2025-01-16Thomas B. Ottoboni | pending |
| COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENTA61K 47/34, A61P 25/04, A61P 23/00, A61P 29/00, A61K 9/0019, A61K 9/0024, A61K 31/00, A61K 31/167, A61K 31/245, A61K 31/445, A61K 31/47, A61K 47/12Filed as Heron Therapeutics, Inc.2024-05-28Thomas B. Ottoboni | pending |
| VIAL ACCESS NEEDLE DEVICEFiled as HERON THERAPEUTICS, INC.2024-03-15LEE ANN LYNN GIROTTI | pending |
| VIAL ACCESS NEEDLE DEVICEA61J 1/201, A61J 1/2096, A61J 1/2055, A61J 1/16Filed as Heron Therapeutics, Inc.2024-03-15Lee Ann Lynn Girotti | pending |
| METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTA61K 9/1075, G06F 16/9038, G06N 20/00, G06F 16/90344, G06N 7/01, G06N 5/01, A61K 9/0019, A61K 31/43, A61K 31/435, A61K 31/496, A61K 31/5377, A61K 31/573, A61K 47/10, A61K 47/24, A61K 47/44, G06N 3/126, G06N 5/025, G06N 5/045, A61K2300/00Filed as Heron Therapeutics, Inc.2024-01-19Thomas B. Ottoboni | 12115255 |
| METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTA61K 9/1075, G06F 16/9038, G06N 20/00, G06F 16/90344, A61K 9/0019, A61K 31/43, A61K 31/435, A61K 31/496, A61K 31/5377, A61K 31/573, A61K 47/10, A61K 47/24, A61K 47/44, A61K2300/00Filed as Heron Therapeutics, Inc.2024-01-09Thomas B. Ottoboni | 12115254 |
| METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTA61K 9/0019, A61K 9/107, A61K 31/5377, A61P 43/00, A61P 1/08, A61K 9/0024, A61K 31/573, A61K 47/10, A61K 47/12, A61K 47/18, A61K 47/24, A61K 47/26, A61K 47/44Filed as Heron Therapeutics, Inc.2024-01-09Thomas B. Ottoboni | 12290520 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on HRTX
Company overviewEverything on HRTX in one place, with the price.SEC filingsWhat HRTX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat HRTX's own officers and directors buy and sell.Who owns itEvery manager reporting a position in HRTX.Funds holding itWhich funds and ETFs hold HRTX, and how big a bet.LobbyingWhat HRTX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on HRTX's account, and who they worked for.